Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

This research found humoral responses against SARS-CoV-2 were induced in all recipients of an inactivated SARS-CoV-2 vaccine (BBIBP-CorV) on day 42, with higher neutralising antibody titres seen in the group receiving 4 μg on days 0 and 21 or days 0 and 28.

SPS commentary:

A related Comment notes that by September 2020, there were 39 candidate Covid-19 vaccines being tested in clinical trials and over 200 candidates in preclinical development. This was the first study of an inactivated SARS-CoV-2 vaccine to include participants older than 60 years. The vaccine was similarly immunogenic in older (>60) and younger adults, with less adverse events in the older age group.

The levels of neutralising antibody titres and adverse events reported here are similar to those reported for another β-propiolactone inactivated aluminium-adjuvanted whole-virion SARS-CoV-2 vaccine, and the commentators suggest this indicates the reproducibility of clinical results of similar vaccine modes produced by different manufacturers.

A phase 3 trial of the BBIBP-CorV vaccine is currently underway in Abu Dhabi, United Arab Emirates.

The Lancet Infectious Diseases

Resource links:

Comment